nach oben

Erschienen in:

11.06.2022 | Asthma (V Ortega, Section Editor)

Expert Opinion on Practice Patterns in Mild Asthma After the GINA 2019 Updates: A Major Shift in Treatment Paradigms from a Long-Standing SABA-Only Approach to a Risk Reduction–Based Strategy with the Use of Symptom-Driven (As-Needed) Low-Dose ICS/LABA

verfasst von: Zeynep Ferhan Ozseker, Kurtulus Aksu, Levent Cem Mutlu, Pinar Mutlu, Can Ozturk, The Turkish Respiratory Society, Asthma, Allergic Respiratory Disease Scientific Committee

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This expert opinion, prepared by a panel of chest disease specialists, aims to review the current knowledge on practice patterns in real-life management of mild asthma and to address the relevant updates in asthma treatment by The Global Initiative for Asthma (GINA) to guide clinicians for the best clinical practice in applying these new treatment paradigms.

Recent Findings

On the basis of the emerging body of evidence suggesting the non-safety of short-acting β2-agonists (SABA)-only therapy and comparable efficacy of the as-needed inhaled corticosteroids (ICS)-formoterol combinations with maintenance ICS regimens, GINA recently released their updated Global Strategy for Asthma Management and Prevention Guide (2019). The new GINA 2019 recommendations no longer support the SABA-only therapy in mild asthma but instead includes new off-label recommendations such as symptom-driven (as-needed) low-dose ICS-formoterol and “low dose ICS taken whenever SABA is taken.” The GINA 2019 asthma treatment recommendations include a major shift from long-standing approach of clinical practice regarding the use of symptom-driven SABA treatment alone in the management of mild asthma.

Summary

This expert opinion supports the transition from a long-standing SABA-only approach to a risk reduction–based strategy, with the use of symptom-driven (as-needed) low-dose ICS/LABA in mild asthma patients, particularly in those with poor adherence to controller medications. The thoughtful and comprehensive approach of clinicians to these strategies is important, given that the exact far-reaching impact of this major change in management of mild asthma in the real-world settings will only be clarified over time.

Holgate ST. Pathogenesis of asthma. Clin Exp Allergy. 2008;38(6):872–97. https://doi.org/10.1111/j.1365-2222.2008.02971.x.CrossRefPubMed

Ishmael FT. The inflammatory response in the pathogenesis of asthma. J Am Osteopath Assoc. 2011;111(11 Suppl 7):S11–7.PubMed

•• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2020. https://ginasthma.org/. Accessed 5 May 2021. The updated Global Strategy for Asthma Management and Prevention Guide was released by Global Initiative for Asthma (GINA) in 2019, based on the growing evidence on the non-safety of SABA-only therapy and superiority of the as-needed ICS-formoterol combinations over maintenance ICS regimens.

Mulgirigama A, Barnes N, Fletcher M, Pedersen S, Pizzichini E, Tsiligianni I. A review of the burden and management of mild asthma in adults - implications for clinical practice. Respir Med. 2019;152:97–104. https://doi.org/10.1016/j.rmed.2019.04.024.CrossRefPubMed

Choby GW, Lee S. Pharmacotherapy for the treatment of asthma: current treatment options and future directions. Int Forum Allergy Rhinol. 2015;5(Suppl1):S35-40. https://doi.org/10.1002/alr.21592.CrossRefPubMed

Global Initiative for Asthma (GINA). What’s new in GINA 2021?. 2021. https://ginasthma.org/. Accessed 5 May 2021.

•• Muneswarao J, Hassali MA, Ibrahim B, Saini B, Ali IAH, Verma AK. It is time to change the way we manage mild asthma: an update in GINA 2019. Respir Res. 2019;20(1):183. https://doi.org/10.1186/s12931-019-1159-y. The new GINA 2019 recommendations for asthma treatment no longer support the symptom-driven SABA-only therapy in mild asthma, instead offer new off-label approaches for the two treatment steps (Steps 1 and 2), including symptom-driven (as-needed) low dose ICS-formoterol and “low dose ICS taken whenever SABA is taken”.

Lugogo N, Gilbert I, Tkacz J, Gandhi H, Goshi N, Lanz MJ. Real-world patterns and implications of short-acting β2-agonist use in patients with asthma in the United States. Ann Allergy Asthma Immunol. 2021;126(6):681-9.e1. https://doi.org/10.1016/j.anai.2021.01.024.CrossRefPubMed

Laforest L, Licaj I, Devouassoux G, Chatte G, Martin J, Van Ganse E. Asthma drug ratios and exacerbations: claims data from universal health coverage systems. Eur Respir J. 2014;43(5):1378–86. https://doi.org/10.1183/09031936.00100113.CrossRefPubMed

10.

Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992;326(8):501–6. https://doi.org/10.1056/NEJM199202203260801.CrossRefPubMed

11.

O’Byrne PM, Reddel HK, Beasley R. The management of mild asthma. Eur Respir J. 2021;57(4):2003051. https://doi.org/10.1183/13993003.03051-2020.CrossRefPubMed

12.

Rajan S, Gogtay NJ, Konwar M, Thatte UM. The global initiative for asthma guidelines (2019): change in the recommendation for the management of mild asthma based on the SYGMA-2 trial - A critical appraisal. Lung India. 2020;37(2):169–73. https://doi.org/10.4103/lungindia.lungindia_308_19.CrossRefPubMedPubMedCentral

13.

Global Asthma Network. The global asthma report. 2014. http://globalasthmareport.org/2014/Global_Asthma_Report_2014.pdf. Accessed 20 Feb 2021.

14.

Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1. https://doi.org/10.1186/s40733-016-0029-3.CrossRefPubMedPubMedCentral

15.

Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7:246. https://doi.org/10.3389/fped.2019.00246.CrossRefPubMedPubMedCentral

16.

Enilari O, Sinha S. The global impact of asthma in adult populations. Ann Glob Health. 2019;85(1):2. https://doi.org/10.5334/aogh.2412.

17.

To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204. https://doi.org/10.1186/1471-2458-12-204.CrossRefPubMedPubMedCentral

18.

Kurt E, Metintas S, Basyigit I, Bulut I, Coskun E, Dabak S, et al. Prevalence and risk factors of allergies in Turkey (PARFAIT): results of a multicentre cross-sectional study in adults. Eur Respir J. 2009;33(4):724–33. https://doi.org/10.1183/09031936.00082207.CrossRefPubMed

19.

Sekerel BE, Gemicioglu B, Soriano JB. Asthma insights and reality in Turkey (AIRET) study. Respir Med. 2006;100(10):1850–4. https://doi.org/10.1016/j.rmed.2006.01.024.CrossRefPubMed

20.

Altman MC, Lai Y, Nolin JD, Long S, Chen CC, Piliponsky AM, et al. Airway epithelium-shifted mast cell infiltration regulates asthmatic inflammation via IL-33 signaling. J Clin Invest. 2019;129(11):4979–91. https://doi.org/10.1172/JCI126402.CrossRefPubMedPubMedCentral

21.

Durrani SR, Viswanathan RK, Busse WW. What effect does asthma treatment have on airway remodeling? Current perspectives J Allergy Clin Immunol. 2011;128:439–48. https://doi.org/10.1016/j.jaci.2011.06.002.CrossRefPubMed

22.

Vignola AM, Chanez P, Campbell AM, Souques F, Lebel B, Enander I, et al. Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med. 1998;157:403–9. https://doi.org/10.1164/ajrccm.157.2.96-08040.CrossRefPubMed

23.

Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol. 2015;5(Suppl 1):S2-6. https://doi.org/10.1002/alr.21609.CrossRefPubMed

24.

Banno A, Reddy AT, Lakshmi SP, Reddy RC. Bidirectional interaction of airway epithelial remodeling and inflammation in asthma. Clin Sci (Lond). 2020;134(9):1063–79. https://doi.org/10.1042/CS20191309.CrossRef

25.

Russell RJ, Brightling C. Pathogenesis of asthma: implications for precision medicine. Clin Sci (Lond). 2017;131(14):1723–35. https://doi.org/10.1042/CS20160253.CrossRef

26.

Rytilä P, Metso T, Heikkinen K, Saarelainen P, Helenius IJ, Haahtela T. Airway inflammation in patients with symptoms suggesting asthma but with normal lung function. Eur Respir J. 2000;16(5):824–30. https://doi.org/10.1183/09031936.00.16582400.CrossRefPubMed

27.

Tillie-Leblond I, Montani D, Crestani B, de Blic J, Humbert M, Tunon-de-Lara M, et al. Relation between inflammation and symptoms in asthma. Allergy. 2009;64(3):354–67. https://doi.org/10.1111/j.1398-9995.2009.01971.x.CrossRefPubMed

28.

Mogensen I, Alving K, Jacinto T, Fonseca J, Janson C, Malinovschi A. Simultaneously elevated FeNO and blood eosinophils relate to asthma morbidity in asthmatics from NHANES 2007–12. Clin Exp Allergy. 2018;48(8):935–43. https://doi.org/10.1111/cea.13137.CrossRefPubMed

29.

Mogensen I, Alving K, Bjerg A, Borres MP, Hedlin G, Sommar J, et al. Simultaneously elevated exhaled nitric oxide and serum-eosinophil cationic protein relate to recent asthma events in asthmatics in a cross-sectional population-based study. Clin Exp Allergy. 2016;46(12):1540–8. https://doi.org/10.1111/cea.12792.CrossRefPubMed

30.

van der Valk RJ, Baraldi E, Stern G, Frey U, de Jongste JC. Daily exhaled nitric oxide measurements and asthma exacerbations in children. Allergy. 2012;67(2):265–71. https://doi.org/10.1111/j.1398-9995.2011.02734.x.CrossRefPubMed

31.

Jeffery PK, Haahtela T. Allergic rhinitis and asthma: inflammation in a one-airway condition. BMC Pulm Med. 2006;6 Suppl 1(Suppl 1):S5. https://doi.org/10.1186/1471-2466-6-S1-S5

32.

Dusser D, Montani D, Chanez P, de Blic J, Delacourt C, Deschildre A, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;62(6):591–604. https://doi.org/10.1111/j.1398-9995.2007.01394.x.CrossRefPubMed

33.

Levy ML, Andrews R, Buckingham R, Evans H, Francis C, Houston R, et al. Why asthma still kills: the national review of asthma deaths (NRAD) confidential enquiry report. London, UK: Royal College of Physicians. 2014. http://www.rcplondon.ac.uk/sites/default/files/why-asthma-still-kills-full-report.pdf. Accessed 20 Feb 2021.

34.

Ding B, DiBonaventura M, Karlsson N, Ling X. A cross-sectional assessment of the prevalence and burden of mild asthma in urban China using the 2010, 2012, and 2013 China National Health and Wellness Surveys. J Asthma. 2017;54(6):632–43. https://doi.org/10.1080/02770903.2016.1255750.CrossRefPubMed

35.

Bloom CI, Nissen F, Douglas IJ, Smeeth L, Cullinan P, Quint JK. Exacerbation risk and characterisation of the UK’s asthma population from infants to old age. Thorax. 2018;73(4):313–20. https://doi.org/10.1136/thoraxjnl-2017-210650.CrossRefPubMed

36.

FitzGerald JM, Barnes PJ, Chipps BE, Jenkins CR, O’Byrne PM, Pavord ID, et al. The burden of exacerbations in mild asthma: a systematic review. ERJ Open Res. 2020;6(3):00359–2019. https://doi.org/10.1183/23120541.00359-2019.CrossRefPubMedPubMedCentral

37.

Chuchalin A, Jacques L, Frith L. Salmeterol/fluticasone propionate via Diskus™ once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids. Clin Drug Investig. 2008;28(3):169–81. https://doi.org/10.2165/00044011-200828030-00004.CrossRefPubMed

38.

Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361(9363):1071–6. https://doi.org/10.1016/S0140-6736(03)12891-7.CrossRefPubMed

39.

Fuhlbrigge AL, Adams RJ, Guilbert TW, Grant E, Lozano P, Janson SL, et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med. 2002;166(8):1044–9. https://doi.org/10.1164/rccm.2107057.CrossRefPubMed

40.

Crompton G. A brief history of inhaled asthma therapy over the last fifty years. Prim Care Respir J. 2006;15(6):326–31. https://doi.org/10.1016/j.pcrj.2006.09.002.CrossRefPubMedPubMedCentral

41.

Foster JM, Beasley R, Braithwaite I, Harrison T, Holliday M, Pavord I, et al. Patient experiences of as-needed budesonide-formoterol by Turbuhaler® for treatment of mild asthma; a qualitative study. Respir Med. 2020;175: 106154. https://doi.org/10.1016/j.rmed.2020.106154.CrossRefPubMed

42.

Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332–6. https://doi.org/10.1056/NEJM200008033430504.CrossRefPubMed

43.

Nwaru BI, Ekstrom M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55(4):1901872. https://doi.org/10.1183/13993003.01872-2019.CrossRefPubMedPubMedCentral

44.

Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002;57(10):880–4. https://doi.org/10.1136/thorax.57.10.880.CrossRefPubMedPubMedCentral

45.

Reddel HK, Ampon RD, Sawyer SM, Peters MJ. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open. 2017;7(9): e016688. https://doi.org/10.1136/bmjopen-2017-016688.CrossRefPubMedPubMedCentral

46.

FitzGerald JM, Tavakoli H, Lynd LD, Al Efraij K, Sadatsafavi M. The impact of inappropriate use of short acting beta agonists in asthma. Respir Med. 2017;131:135–40. https://doi.org/10.1016/j.rmed.2017.08.014.CrossRefPubMed

47.

Paris J, Peterson EL, Wells K, Pladevall M, Burchard EG, Choudhry S, et al. Relationship between recent short-acting beta-agonist use and subsequent asthma exacerbations. Ann Allergy Asthma Immunol. 2008;101(5):482–7. https://doi.org/10.1016/S1081-1206(10)60286-4.CrossRefPubMedPubMedCentral

48.

Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991;325(6):388–92. https://doi.org/10.1056/NEJM199108083250603.CrossRefPubMed

49.

Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al. GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53(6):1901046. https://doi.org/10.1183/13993003.01046-2019.CrossRefPubMed

50.

Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009. https://doi.org/10.1038/npjpcrm.2014.9.CrossRefPubMedPubMedCentral

51.

Janson C, Menzies-Gow A, Nan C, Nuevo J, Papi A, Quint JK, et al. SABINA: an overview of short-acting β2-agonist use in asthma in European countries. Adv Ther. 2020;37(3):1124–35. https://doi.org/10.1007/s12325-020-01233-0.CrossRefPubMedPubMedCentral

52.

Rabe K, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J. 2000;16(5):802–7. https://doi.org/10.1183/09031936.00.16580200.CrossRefPubMed

53.

Lynd LD, Guh DP, Paré PD, Anis AH. Patterns of inhaled asthma medication use: a 3-year longitudinal analysis of prescription claims data from British Columbia. Canada Chest. 2002;122(6):1973–81. https://doi.org/10.1378/chest.122.6.1973.CrossRefPubMed

54.

Makhinova T, Barner JC, Richards KM, Rascati KL. Asthma controller medication adherence, risk of exacerbation, and use of rescue agents among Texas Medicaid patients with persistent asthma. J Manag Care Spec Pharm. 2015;21(12):1124–32. https://doi.org/10.18553/jmcp.2015.21.12.1124

55.

Stoloff SW, Boushey HA. Severity, control, and responsiveness in asthma. J Allergy Clin Immunol. 2006;117(3):544–8. https://doi.org/10.1016/j.jaci.2006.01.005.CrossRefPubMed

56.

Partridge M, van der Molen T, Myrseth S-E, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13. https://doi.org/10.1186/1471-2466-6-13.CrossRefPubMedPubMedCentral

57.

Bårnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care. 2015;60(3):455–68. https://doi.org/10.4187/respcare.03200.CrossRefPubMed

58.

Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J. 1998;12(5):1209–18. https://doi.org/10.1183/09031936.98.12051209.CrossRefPubMed

59.

Davidsen JR. Drug utilization and asthma control among young Danish adults with asthma. Analyses of trends and determinants. Dan Med J. 2012;59(8):B4501.

60.

Kandane-Rathnayake RK, Matheson MC, Simpson JA, Tang ML, Johns DP, Mészáros D, et al. Adherence to asthma management guidelines by middle-aged adults with current asthma. Thorax. 2009;64(12):1025–31. https://doi.org/10.1136/thx.2009.118430.CrossRefPubMed

61.

Ding B, Small M. Disease burden of mild asthma: findings from a cross-sectional real-world survey. Adv Ther. 2017;34(5):1109–27. https://doi.org/10.1007/s12325-017-0520-0.CrossRefPubMedPubMedCentral

62.

Bender BG, Rankin A, Tran ZV, Wamboldt FS. Brief-interval telephone surveys of medication adherence and asthma symptoms in the Childhood Asthma Management Program Continuation Study. Ann Allergy Asthma Immunol. 2008;101(4):382–6. https://doi.org/10.1016/S1081-1206(10)60314-6.CrossRefPubMedPubMedCentral

63.

Gerald JK, Carr TF, Wei CY, Holbrook JT, Gerald LB. Albuterol overuse: a marker of psychological distress? J Allergy Clin Immunol Pract. 2015;3(6):957–62. https://doi.org/10.1016/j.jaip.2015.06.021.CrossRefPubMedPubMedCentral

64.

Bakirtas A, Kutlu A, Baccioglu A, Erkekol FO, Bavbek S, Kalayci O, et al. Physicians’ preference for controller medication in mild persistent asthma. Respir Med. 2017;131:236–40. https://doi.org/10.1016/j.rmed.2017.08.029.CrossRefPubMed

65.

Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest. 2000;117(2):542–50. https://doi.org/10.1378/chest.117.2.542.CrossRefPubMed

66.

O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–76. https://doi.org/10.1056/NEJMoa1715274.CrossRefPubMed

67.

Bateman ED, Reddel HK, O’Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild Asthma. N Engl J Med. 2018;378(20):1877–87. https://doi.org/10.1056/NEJMoa1715275.CrossRefPubMed

68.

Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020–30. https://doi.org/10.1056/NEJMoa1901963.CrossRefPubMed

69.

Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919–28. https://doi.org/10.1016/S0140-6736(19)31948-8.CrossRefPubMed

70.

Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356(20):2040–52. https://doi.org/10.1056/NEJMoa063861.CrossRefPubMed

71.

Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF Jr, Mauger DT, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, doubleblind, placebo-controlled trial. Lancet. 2011;377(9766):650–7. https://doi.org/10.1016/S0140-6736(10)62145-9.CrossRefPubMedPubMedCentral

72.

Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA. 2012;308(10):987–97. https://doi.org/10.1001/2012.jama.10893.CrossRefPubMedPubMedCentral

73.

Global Initiative for Asthma. Global strategy for asthma management and prevention. 2018. https://ginasthma.org/. Accessed 20 Feb 2021.

Titel: Expert Opinion on Practice Patterns in Mild Asthma After the GINA 2019 Updates: A Major Shift in Treatment Paradigms from a Long-Standing SABA-Only Approach to a Risk Reduction–Based Strategy with the Use of Symptom-Driven (As-Needed) Low-Dose ICS/LABA
verfasst von: Zeynep Ferhan Ozseker
Kurtulus Aksu
Levent Cem Mutlu
Pinar Mutlu
Can Ozturk
The Turkish Respiratory Society, Asthma, Allergic Respiratory Disease Scientific Committee
Publikationsdatum: 11.06.2022
Verlag: Springer US
Erschienen in: Current Allergy and Asthma Reports / Ausgabe 10/2022
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-022-01038-x

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Expert Opinion on Practice Patterns in Mild Asthma After the GINA 2019 Updates: A Major Shift in Treatment Paradigms from a Long-Standing SABA-Only Approach to a Risk Reduction–Based Strategy with the Use of Symptom-Driven (As-Needed) Low-Dose ICS/LABA

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO